Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAGAMET is an injectable small-molecule drug approved in 1977 by GSK, indicating a mature, established therapeutic. The specific indication and mechanism of action are not provided in available data. This product represents a legacy asset in GSK's portfolio with decades of clinical use.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team investment and shift toward generic transition management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAGAMET offers limited growth opportunity given LOE approaching status and zero linked job count; roles are primarily focused on defending market share, managing generic transition, and optimizing supply chain. Career mobility from this product is constrained; consider it a consolidation or transition role rather than a launchpad for advancement.
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.